RecruitingNot ApplicableNCT06900374

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients

RF-Vaginale : Randomised Phase III Trial Evaluating the Efficacy and Safety of Vaginal Radiofrequency in the Management of Vulvovaginal Atrophy and Dryness in Patients Treated for Breast Cancer


Sponsor

Centre Oscar Lambret

Enrollment

75 participants

Start Date

Jun 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer. Patients will be randomly assigned to one of two parallel treatment groups until the six-month assessment: The first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators. The second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.


Eligibility

Sex: FEMALEMin Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether vaginal radiofrequency treatment can relieve vaginal dryness and discomfort in breast cancer patients who are taking hormone-blocking therapy (aromatase inhibitors), which often causes these symptoms. **You may be eligible if...** - You are over 40 years old - You have disabling vaginal dryness despite using moisturizing treatments - You are receiving adjuvant (follow-up) treatment for breast cancer - You have been on aromatase inhibitors (with or without LHRH agonist) for at least 3 months, with at least 12 more months planned **You may NOT be eligible if...** - You have an active urinary tract infection - You have a pacemaker or an IUD (intrauterine device) - You are pregnant - You have a skin or mucosal disease in the vaginal area (such as lichen sclerosus, psoriasis, or active infection) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEGynWave-360

For patients randomized to the experimental group: 3 sessions of 20 minutes each, spaced 4 to 6 weeks apart (M0, M1, M2) ideally, with +/- 1 maintenance session between 8 and 12 months after the first session (M8-12).

OTHERLocal hydratation

Reference treatment combining local hydration (hyaluronic acid-based treatment, 3 times a week), with the possibility of using associated measures at the investigator's discretion (physiotherapy, vaginal dilators, etc.).


Locations(1)

Centre Oscar Lambret

Lille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06900374


Related Trials